That's after testing showed it contained trace amounts of a cancer-causing material.
Prinston Pharmaceuticals announced one lot of Irbesartan tablets and seven lots of Irbesartan HCTZ tablets are affected.
RELATED: Blood pressure medicine recall expands amid cancer concerns
The company said the medication contained unacceptable levels of NDEA, a likely carcinogen.
The ingredients were manufactured by a pharmaceuticals company in China.
Since July, the factory has been linked to several recalls of regularly-prescribed blood pressure drugs.